glp-1 drugs sleep apnea Might Help Quell FDA approves weight loss drug

dots represent all points outside 1.5 times the IQR

By 2020, an estimated 2.2 billion adults worldwide were suffering from overweight and obesity, and it is predicted that this number will increase to 3.3 billion by 2035 [1]

Due to the exponential growth of Ozempic and other GLP-1s, it makes sense for plan sponsors to manage this class of drugs

Addressing these challenges will require strategies such as price negotiations, inclusion in essential medicines lists, and the integration of digital health tools to support adherence and real-time monitoring

Amycretin oral is another important future disruptor

Not everybody responds equally well to these treatments, and its impossible to predict how effective any specific weight loss medication will be for you